Liva Pharmaceuticals receives approval from the USFDA for its sANDA, Ranitidine Injection USP
Deepthi | Myequity news | Date : 11-12-2018 12:30:00 IST
Liva Pharmaceuticals Limited, a wholly-owned subsidiary company of Cadila Healthcare Limited has received the approval from the USFDA for its supplemental abbreviated new drug application (sANDA), Ranitidine Injection USP, 25 mg/mL, 2 mL Single dose vials and 6 mL Multi-dose vials. It will be manufactured at Liva Pharma’s manufacturing facility at Vadodara and is the first product to be approved from this site for marketing in the US. About Zydus Cadila:
Ranitidine belongs to the class of medications called H2—antagonists and is used to treat stomach and duodenal (intestinal) ulcers, and prevent them from recurring. It is also used to treat gastroesophageal reflux disease (GERD) and Zollinger-Ellison Syndrome. The injectable form of ranitidine is given for short-term treatment of these conditions when a patient is unable to take this medication orally.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research—based pharmaceutical company by 2020